Wellcome commits £ 10 million to DNDi to develop new generation of oral leishmaniasis drugs

(Drugs for Neglected Diseases Initiative) Wellcome has committed over £ 10 million to the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization, to develop new treatments for leishmaniasis, one of the world's most devastating parasitic diseases.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news